Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing
NCT02998112Phase 4Unknown
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of allogeneic fecal microbiota in ulcerative colitis (UC) (2 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoints: Clinical remission at 12 weeks and Clinical improvement at 12 weeks. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02998112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998112.